13F-HR filed by Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2022-06-30, filed 2022-08-15, with 23 holding rows worth $501,529,000.
- Accession
- 0001855655-22-000008
- Filer
- CIK 1855655
- Filed
- 2022-08-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2022
A holdings report, 23 entries on the cover page, a total value of $501,529,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $501,530,000 with VALUE read as thousands by filing date, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| LEGEND BIOTECH CORP | 52490G102 | SPONSORED ADS | 978,596 | $53,823,000 | thousands by filing date | |
| GLOBAL BLOOD THERAPEUTICS USD | 37890U108 | COM | 1,445,566 | $46,186,000 | thousands by filing date | |
| MIRATI THERAPEUTICS INC | 60468T105 | COM | 659,968 | $44,304,000 | thousands by filing date | |
| SIERRA ONCOLOGY INC | 82640U404 | CMN | 801,314 | $44,064,000 | thousands by filing date | |
| INCYTE CORP COM | 45337C102 | Stock | 556,043 | $42,243,000 | thousands by filing date | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 432,170 | $40,175,000 | thousands by filing date | |
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 163,066 | $38,425,000 | thousands by filing date | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 88,816 | $33,651,000 | thousands by filing date | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 667,417 | $24,901,000 | thousands by filing date | |
| ARVINAS INC | 04335A105 | COM | 517,406 | $21,778,000 | thousands by filing date | |
| BICYCLE THERAPEUTICS PLC-ADR | 088786108 | SPONSORED ADS | 1,048,516 | $17,594,000 | thousands by filing date | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 876,156 | $16,857,000 | thousands by filing date | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 1,306,569 | $15,117,000 | thousands by filing date | |
| MERUS N V | N5749R100 | COM | 452,244 | $10,239,000 | thousands by filing date | |
| ESPERION THERAPEUTICS INC NEW COM | 29664W105 | Stock | 1,408,050 | $8,955,000 | thousands by filing date | |
| TG THERAPEUTICS INC COM | 88322Q108 | Stock | 1,964,709 | $8,350,000 | thousands by filing date | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 826,779 | $7,036,000 | thousands by filing date | |
| ENANTA PHARMACEUTICALS INC | 29251M106 | COM | 148,216 | $7,006,000 | thousands by filing date | |
| VOR BIOPHARMA INC | 929033108 | COM | 1,304,300 | $6,482,000 | thousands by filing date | |
| OYSTER POINT PHARMA INC | 69242L106 | COMMON STOCK | 1,333,330 | $5,773,000 | thousands by filing date | |
| GRACELL BIOTECHNOLOGIES INC | 38406L103 | ADR | 783,445 | $4,309,000 | thousands by filing date | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 850,961 | $3,710,000 | thousands by filing date | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 73,149 | $552,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001855655-22-000008 | this filing | 2022-08-15 | acceptance time not in the bulk data set |